Methotrexate adjuvants to reduce toxicity and methods for using the same
USRE48253E1 · kind E1 · reissue
3Cited by
10References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 29, 2018 |
| Grant date | Oct 13, 2020 |
| Priority date | — |
| Expiry date | Jun 29, 2038 |
Classification
- Technology area (CPC —)General
Abstract
Methods are provided for using methotrexate (MTX) active agents in which reduced host toxicity is observed. Aspects of the methods include administering to a subject an effective amount of an MTX active agent in conjunction with a MTX toxicity-reducing adjuvant, such as a 2,2′-anhydropyrimidine, a derivative thereof or a uridine phosphorylase inhibitor. Also provided are compositions and kits that find use in practicing embodiments of the invention. The methods and compositions find use in a variety of applications, including the treatment of a variety of different disease conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.